Ningqingtan^® Acetylcysteine Effervescent Tablets are indicated for the treatment of chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB), emphysema (PE), and other chronic respiratory diseases characterized by excessive and thick mucus secretion. The mechanism of action includes: Directly breaking down thick mucus. Enhancing ciliary activity to clear the airways and promote mucus expulsion. Inhibiting bacterial adhesion and providing synergistic antibacterial effects. Offering antioxidant effects through multiple pathways, helping to regulate oxidative stress and improving lung function.

Ningqingtan^® Acetylcysteine Effervescent Tablets were approved for marketing in April 2024. Using an effervescent formulation and adjusted API acidity, the product reduces gastrointestinal irritation while improving stability and safety. It is especially suitable for long-term management of chronic respiratory diseases like COPD and bronchiectasis, serving as an antioxidant treatment for full-course respiratory disease management.